Article History
Received: 30 January 2019
Accepted: 6 August 2019
First Online: 19 August 2019
Competing Interests
: Paul Ning-Man Cheng is the chief executive officer of Bio-Cancer Treatment International Limited and holds stocks or shares in Bio-Cancer Treatment International Limited. The other authors have no conflict of interest.